MX2023002525A - Nuevos compuestos. - Google Patents
Nuevos compuestos.Info
- Publication number
- MX2023002525A MX2023002525A MX2023002525A MX2023002525A MX2023002525A MX 2023002525 A MX2023002525 A MX 2023002525A MX 2023002525 A MX2023002525 A MX 2023002525A MX 2023002525 A MX2023002525 A MX 2023002525A MX 2023002525 A MX2023002525 A MX 2023002525A
- Authority
- MX
- Mexico
- Prior art keywords
- novel compounds
- compounds
- formula
- relates
- related aspects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2013728.7A GB202013728D0 (en) | 2020-09-01 | 2020-09-01 | Novel compounds |
| PCT/GB2021/052261 WO2022049376A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002525A true MX2023002525A (es) | 2023-05-17 |
Family
ID=72749708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002525A MX2023002525A (es) | 2020-09-01 | 2021-09-01 | Nuevos compuestos. |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202013731D0 (en) | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel cmpounds |
| WO2023209651A1 (en) * | 2022-04-29 | 2023-11-02 | Dong-A St Co., Ltd. | Bicycle compounds as tead inhibitor |
| GB202300833D0 (en) | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| CN119306612B (zh) * | 2023-07-14 | 2026-03-20 | 中国科学院大连化学物理研究所 | 一种反式氨基茚满的制备方法 |
| CN121866248A (zh) | 2023-09-05 | 2026-04-14 | Nrg治疗有限公司 | 作为mptp抑制剂起作用的吡啶衍生物 |
| GB202410534D0 (en) | 2024-07-18 | 2024-09-04 | Nrg Therapeutics Ltd | Novel method and uses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2852659B2 (ja) * | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
| JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
| AU2002354476A1 (en) | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| JP2006512306A (ja) * | 2002-08-29 | 2006-04-13 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途 |
| JP2006160916A (ja) * | 2004-12-08 | 2006-06-22 | Fuji Photo Film Co Ltd | インクジェット用インク組成物及びインクジェット記録方法 |
| JP5495206B2 (ja) | 2006-10-24 | 2014-05-21 | コンジエニア・ソシエタ・ア・レスポンサビリタ・リミタータ | 変性性組織障害をmptの阻害により防止するための薬剤としてのフェニル置換マレイミド |
| EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| WO2011087051A1 (ja) | 2010-01-14 | 2011-07-21 | 国立大学法人金沢大学 | S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬 |
| JP5990106B2 (ja) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤 |
| WO2016090371A2 (en) | 2014-12-05 | 2016-06-09 | An2H Discovery Limited | Parkin ligase activation methods and compositions |
| CA2884607A1 (en) | 2015-03-11 | 2016-09-11 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
| WO2019002624A1 (de) | 2017-06-30 | 2019-01-03 | Kleuser, Burkhard | Mittel zur therapie entzündlicher darmerkrankungen |
| GB202013731D0 (en) | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel cmpounds |
-
2020
- 2020-09-01 GB GBGB2013728.7A patent/GB202013728D0/en not_active Ceased
-
2021
- 2021-09-01 MX MX2023002525A patent/MX2023002525A/es unknown
- 2021-09-01 CN CN202180053567.3A patent/CN116096705A/zh active Pending
- 2021-09-01 US US18/023,558 patent/US12630516B2/en active Active
- 2021-09-01 IL IL300900A patent/IL300900A/en unknown
- 2021-09-01 ES ES21769789T patent/ES3055772T3/es active Active
- 2021-09-01 EP EP21769789.5A patent/EP4208442B1/en active Active
- 2021-09-01 AU AU2021337195A patent/AU2021337195A1/en not_active Abandoned
- 2021-09-01 KR KR1020237007646A patent/KR20230069915A/ko not_active Withdrawn
- 2021-09-01 JP JP2023537723A patent/JP7784430B2/ja active Active
- 2021-09-01 CA CA3190645A patent/CA3190645A1/en active Pending
- 2021-09-01 WO PCT/GB2021/052261 patent/WO2022049376A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539694A (ja) | 2023-09-15 |
| WO2022049376A1 (en) | 2022-03-10 |
| JP7784430B2 (ja) | 2025-12-11 |
| US12630516B2 (en) | 2026-05-19 |
| KR20230069915A (ko) | 2023-05-19 |
| CN116096705A (zh) | 2023-05-09 |
| EP4208442B1 (en) | 2025-10-22 |
| EP4208442A1 (en) | 2023-07-12 |
| US20240067614A1 (en) | 2024-02-29 |
| ES3055772T3 (en) | 2026-02-16 |
| CA3190645A1 (en) | 2022-03-10 |
| GB202013728D0 (en) | 2020-10-14 |
| AU2021337195A1 (en) | 2023-03-02 |
| IL300900A (en) | 2023-04-01 |
| EP4208442C0 (en) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500655A1 (en) | Compounds | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| AU2020317609A8 (en) | Novel heteroaryl-triazole compounds as pesticides | |
| MX2020009347A (es) | Picolinamidas como fungicidas. | |
| MY203303A (en) | Compounds | |
| PH12020551760A1 (en) | Pyridazinones as parp7 inhibitors | |
| MY209340A (en) | Egfr inhibitor for the treatment of cancer | |
| AU2018274723A1 (en) | Benzimidazolone derived inhibitors of BCL6 | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| MX2023012907A (es) | Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3). | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| MX2023011864A (es) | Inhibidores de dihidroorotato deshidrogenasa deuterados. | |
| MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| ZA202101487B (en) | Novel compounds | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| EP4706394A3 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| MX2025008454A (es) | Inhibidores de mptp | |
| MX2025013714A (es) | Agonistas espiromacrociclicos de receptores de orexina 2 | |
| PH12020550252B1 (en) | Novel phenylpyridine derivative and pharmaceutical composition comprising the same | |
| MX2025005972A (es) | Compuestos novedosos como moduladores de la inhibicion de la proteina 3 que contiene un dominio de pirina de la familia de receptores similares al dominio de oligomerizacion de union a nucleotidos (nlrp3) | |
| ZA202400823B (en) | Inhibitors of transglutaminases | |
| ZA202400821B (en) | Inhibitors of transglutaminases | |
| DOP2026000099A (es) | Nuevos compuestos |